98%
921
2 minutes
20
Oocyte and embryo cryopreservation before gonadotoxic treatment are established methods to increase the likelihood of live births. Although several sociodemographic factors were found to be associated with undergoing fertility preservation (FP) treatment, clinical characteristics such as planned immediate chemotherapy were not fully investigated. We aimed to investigate whether the planned immediate chemotherapy is related to the decision to undergo oocyte/embryo cryopreservation for FP with adjustment for other clinical characteristics. This institutional cohort study included 491 premenopausal women aged 19 years or older who visited the FP clinic at a tertiary medical center between 2006 and 2019. The primary outcome was whether the participants underwent oocyte/embryo cryopreservation. We evaluated the odds ratios (ORs) and corresponding 95% confidence intervals (CIs) of undergoing oocyte/embryo cryopreservation according to whether immediate chemotherapy was planned using univariable and multivariable logistic regression. Women scheduled for immediate chemotherapy were much less likely to undergo oocyte/embryo cryopreservation than women not scheduled for immediate chemotherapy (OR = 0.46, 95% CI 0.27-0.76) in univariable logistic regression analysis. After adjustment for covariates such as marital status, type of malignancies, and calendar year period, women scheduled for immediate chemotherapy were still less likely to undergo oocyte/embryo cryopreservation than women not scheduled for immediate chemotherapy (OR = 0.31, 95% CI: 0.17-0.56). The association was not different according to the type of malignancies ( for interaction = 0.13). Regarding breast cancer, the OR for undergoing oocyte/embryo cryopreservation in women scheduled for immediate chemotherapy was robust compared with those not planned for immediate chemotherapy (OR = 0.25, 95% CI: 0.12-0.53). The present study demonstrated that planned immediate chemotherapy was negatively associated with undergoing oocyte/embryo cryopreservation. This information can be helpful for FP counseling.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/jayao.2023.0180 | DOI Listing |
Semin Reprod Med
August 2025
Department of Reproductive Medicine and Fertility Preservation, Université Paris-Saclay, Assistance Publique Hôpitaux de Paris, Antoine Beclère Hospital, Clamart, France.
Cervical cancer (CC) is one of the most common malignancies affecting young women of childbearing age, making fertility preservation (FP) a pivotal consideration in its management. The feasibility of FP techniques depends on the cancer stage and oncological treatments. In early-stage CC, fertility-sparing surgery can be offered for young patients wishing to preserve fertility without compromising oncological safety.
View Article and Find Full Text PDFInt J Gynaecol Obstet
July 2025
Department of Obstetrics and Gynaecology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, SAR, China.
Cancer diagnoses in patients of reproductive age require balancing urgent oncological treatment with the need to preserve fertility. This FIGO Best Practice Advice outlines key considerations for fertility management in this population given the rising cancer incidence among young women and the reproductive risks posed by cancer treatments. The guidance evaluates the impact of chemotherapy, radiotherapy, surgery, and emerging therapies-such as targeted agents and immunotherapies-on gonadal function and fertility.
View Article and Find Full Text PDFCryobiology
June 2025
Institute of Biothermal Science & Technology, University of Shanghai for Science and Technology, Shanghai, 200093, China; Shanghai Collaborative Innovation Center for Tumor Energy Therapy, Shanghai, 200093, China; Shanghai Technical Service Platform for Cryopreservation of Biological Resources, Shan
Oocyte/embryo vitrification is one of the basic techniques employed in assisted reproduction and fertility preservation. However, the current process typically requires manual operation by experienced embryologists, which is both time-consuming and exhibits inconsistent outcomes. To resolve this issue, we herein developed an automated vitrification device for oocytes/embryos.
View Article and Find Full Text PDFReprod Biomed Online
April 2025
Department of Obstetrics and Gynecology, Koç University School of Medicine, Istanbul, Turkey.; ART Fertility Clinics, Dubai, United Arab Emirates.. Electronic address:
Conventional ovarian stimulation protocols were designed for fresh embryo transfer. They start in the early follicular phase, i.e.
View Article and Find Full Text PDFExpert Opin Pharmacother
May 2025
Innovation Institute for Fertility Preservation, Newyork, CT, USA.
Introduction: Cancer is one of the major causes of human death, and anti-cancer therapy often results in premature ovarian failure and infertility, depending on factors such as age, initial ovarian reserve, and chemotherapy type and dose. Fertility preservation procedures, such as oocyte, embryo, and ovarian cortex cryopreservation, can help women achieve pregnancy after cancer treatment. However, the development of pharmacological therapies to protect ovarian function during chemotherapy would represent a significant advancement.
View Article and Find Full Text PDF